Search

everythinglearnresearchcommunity

for

Search:↓

Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.

Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.

A standardized drug development platform is essential for efficient and effective drug repurposing, especially during pandemics.

Danoprevir, remdesivir, and saridegib may effectively inhibit SARS-CoV-2.

Drug repurposing is a faster, cheaper way to develop new treatments using existing drugs.

Solanum nigrum shows promise for treating COVID-19 and its complications, but more research is needed.

COVID-19 can cause or worsen skin issues.

Cepharanthine shows promise as a COVID-19 treatment.

Tailored neurorehabilitation programs improve life quality for post-COVID-19 patients.

Long COVID is complex, affects many survivors, and needs more research for effective treatments.

The updated GRADE guidance advises considering context when interpreting variability in research results and introduces tools for assessing subgroup effects.

Long COVID is a big health problem needing more research and better treatments.

We need safe, affordable drugs to fight coronaviruses effectively.

Certain alkaloids could help create new coronavirus drugs.

An HIV patient's complete hair loss was reversed after switching from lopinavir/ritonavir to nelfinavir.

Indinavir and ritonavir therapy can cause reversible hair loss.

Raltegravir may cause hair loss in some patients.

A man's hair loss was linked to his HIV medication, which improved after changing drugs.

Indinavir therapy can cause reversible skin, hair, and nail darkening.

The medication lopinavir-ritonavir may cause severe hair loss.

Golvatinib shows promise as a treatment for Omicron in elderly patients.

A woman developed Cushing syndrome and adrenal insufficiency from using fluticasone and ritonavir together.

HIV medication ritonavir can increase the effects of nasal sprays like fluticasone, causing Cushing's syndrome.

Indinavir, especially with vitamin A, may cause bone changes, but switching to nelfinavir can reduce these effects.

Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.

50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.